Developing an Internationally-diverse, Linked Genomic and Longitudinal Phenotypic Research Dataset to Accelerate Precision Psychiatry for Patients With Serious Mental Illness

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

This observational study aims to provide new insights into the nature and classification of severe mental illness and dementias that in time should help improve diagnostic practise, and enable the development of new and improved treatments. The investigators will achieve aims by gathering information and biological samples from over 50,000 research participants and then linking this information with participants' electronic health records, genetic and other potential markers of mental illnesses (called biomarkers, derived from biological samples). The investigators will use this resource to analyse how potential risk factors - genetic, other biological and non-biological (related to the participants' life circumstances) - influence participants' experiences, symptoms, and outcomes (both mental and physical health). The investigators will also use advanced analysis to assess whether there may be better ways of grouping together and understanding the experiences of those with severe mental illnesses and dementias. Given the value and importance of this resource for advancing mental health research, the investigators will also make the data available to other researchers to pursue these broad research aims.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 110
Healthy Volunteers: f
View:

• \- All participants must have an electronic health record in a primary or secondary care service.

• Mental Health cohort(s) • Have received a diagnosis and/or treatment/referral for mental illness for MDD, BD, Schizophrenia.

• • Having an available electronic health record

• • Current age 18+ (no upper age limit)

• • Can speak English Dementia cohort

• • Participants aged 18+ (no upper age limit)

• • Currently alive and are, or have been, old age psychiatry patients

• •

• Received relevant diagnosis or referral:

• EITHER

• • Clinical diagnosis of dementia, mild cognitive impairment (MCI) or subjective cognitive impairment (SCI) OR

• • Memory clinic referral

• • Must be willing and able to complete a validated cognitive assessment (MoCA or SLUMS).

• All dementia patients will undergo the extended biomarker analysis.

Locations
Other Locations
United Kingdom
GlobalMinds central study team
RECRUITING
Oxford
Contact Information
Primary
Samantha Yuille, PhD
samantha.yuille@akriviahealth.com
(44) 7827018555
Backup
Byron Tibbitts
byron.tibbitts@akriviahealth.com
Time Frame
Start Date: 2025-05-16
Estimated Completion Date: 2035-07-01
Participants
Target number of participants: 50000
Treatments
Cohort 1
40,000 participants with linked EHR and baseline assessments will provide a DNA sample only, via saliva or blood. This cohort will comprise even distribution across neuropsychiatric disorders including Schizophrenia, Major depressive disorder (MDD), and Bipolar diagnostic groups (approximately 13,300 patients in each group).
Cohort 2
9,000 participants with linked EHR and baseline assessments patients will provide DNA, RNA, peripheral blood mononuclear cells (PBMCs), plasma and serum via blood. This cohort will also comprise even distribution across neuropsychiatric disorders including Schizophrenia, Major depressive disorder (MDD), and Bipolar diagnostic groups (approximately 3000 patients in each group).
Cohort 3
1000 participants with Dementia who have linked EHR and assessments will provide DNA, RNA, peripheral blood mononuclear cells (PBMCs), plasma and serum via blood.
Sponsors
Leads: Akrivia Health
Collaborators: Cardiff University

This content was sourced from clinicaltrials.gov